Idec Zevalin EU delay
Executive Summary
European launch of Idec's Zevalin (ibritumomab) is delayed until the second half of 2003 due to "technical compliance issues" at fill/finish manufacturer DSM Catalytica's Greenville, N.C. facility. Launch will follow EU-mandated facility upgrade at Greenville; facility "modification" will not affect U.S. distribution of the non-Hodgkin's lymphoma therapy, Idec said. Schering AG, which distributes Zevalin outside the U.S., had expected a second half 2002 EU launch. U.S. approval of Zevalin was also delayed by GMP problems at Catalytica; FDA approved Zevalin Feb. 19 (1"The Pink Sheet" Feb. 25, p. 18)...
You may also be interested in...
Idec Zevalin NHL Indication Split By Accelerated/Standard Approval
Idec/Genentech will conduct a postmarketing study of Zevalin in non-Hodgkin's lymphoma patients who have not failed Rituxan therapy to fulfill accelerated approval requirements
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.